Market News Archives

Sunnyvale’s Intuitive Surgical Lifts Outlook as Robotic-Surgery Demand Surges -( $ISRG $SPY )

by Vista Partners LLC October 22, 2025 567Views 0Likes

Intuitive Surgical (NASDAQ: ISRG) delivered a striking third quarter, sending its shares surging 17% on Wednesday and underscoring both the company’s operational strength and the accelerating global embrace of robotic-assisted healthcare. The Sunnyvale, California-based leader in minimally invasive surgery reported quarterly revenue…

Serina Therapeutics CEO Video Unveils FDA Alignment Advancing Parkinson’s Therapy -( $SER $IBB $XBI )

by Vista Partners LLC October 22, 2025 576Views 0Likes

Serina Therapeutics (NYSE American: SER) CEO Steven A. Ledger shared encouraging insights in a recent video presentation about the company’s accelerated FDA regulatory pathway for its lead asset, SER-252, targeting advanced Parkinson’s disease. The video can be viewed here: Serina CEO FDA Alignment…

How Alkermes’ $2.1 Billion Avadel Deal Could Reshape Sleep Disorder Treatments -( $ALKS $AVDL $IBB $XBI )

by Vista Partners LLC October 22, 2025 1210Views 0Likes

Alkermes (ALKS) is making a bold entry into the sleep disorders market with the acquisition of Avadel Pharmaceuticals, a deal valued at up to $2.1 billion. This strategic move gives Alkermes access to LUMRYZ, a once-nightly, FDA-approved treatment for narcolepsy, and sets…

Japanese Pharmaceutical Giant Takeda Bets $11.4 Billion on China’s Innovent to Fuel Next-Gen Cancer Drug Pipeline – ( $TAK $IBB $XBI )

by Vista Partners LLC October 22, 2025 584Views 0Likes

Japanese pharmaceutical giant Takeda Pharmaceutical (TAK) has entered into one of the industry's largest licensing agreements this year, committing up to $11.4 billion to acquire rights to three next-generation cancer therapies from China's Innovent Biologics in a deal that underscores the growing…

Tesla’s Next Move: AI-Focused Future Looms Large Ahead of Q3 Earnings – ( $TSLA $SPY )

by Vista Partners LLC October 22, 2025 544Views 0Likes

Tesla (TSLA) is set to report its third-quarter 2025 earnings today, a report that could serve as a major inflection point for the world’s most prominent electric-vehicle maker. Analysts anticipate revenue near 26.3 billion dollars and earnings per share (EPS) of roughly…

Meta Seals $27 Billion ‘New Era’ AI Data Center Deal With Blue Owl Capital -( $META $MS $KKR $NVDA $OWL )

by Vista Partners LLC October 21, 2025 634Views 0Likes

Meta Platforms has secured a record $27 billion financing package from Blue Owl Capital (OWL) to develop its largest data center yet — a colossal new AI-driven hub in Richland Parish, Louisiana. The deal, structured through a joint venture that keeps…

Biotech Breakout: Minerva Neurosciences Secures $200 Million for Schizophrenia Drug Push -( $NERV $IBB $XBI )

by Vista Partners LLC October 21, 2025 612Views 0Likes

Minerva Neurosciences (NERV) has staged a dramatic comeback on Wall Street Tuesday after the company unveiled a financing agreement worth up to $200 million aimed at advancing its schizophrenia drug candidate, roluperidone, through a pivotal Phase 3 trial and eventual U.S. regulatory…

Hologic’s $18B Sale to Blackstone, TPG Underscores Private Equity’s Push Into Women’s Health -( $BX $HOLX $TPG )

by Vista Partners LLC October 21, 2025 572Views 0Likes

Blackstone (BX) and TPG (TPG) are taking women’s health leader Hologic Inc. (HOLX) private in one of the largest healthcare buyouts of 2025, valuing the Massachusetts-based company at up to $18.3 billion including debt. The all-cash deal, announced Tuesday, will pay Hologic…

Market Mood Shifts On Monday: From Tesla’s Pause to GeoVax’s Surge and Silver’s Shine -( $BYND $GOVX $SPY $TSLA $TKMS $KER.PA $SIL $GLD )

by Vista Partners LLC October 20, 2025 472Views 0Likes

Wall Street’s radar has lit up Monday as a collection of standout corporate and commodity stories shaped the trading landscape, not to mention the shift in understanding with regard to the Whte House's ongoing negation with China and tariffs—from consumer brands clawing…

San Jose’s Rani Therapeutics Secures A Japan Chugai Pharmaceutical $1.085B Collaboration & $60.3M Financing -( $RANI $CHGCY )

by Vista Partners LLC October 17, 2025 446Views 0Likes

Rani Therapeutics Holdings (NASDAQ: RANI) has unveiled a transformative partnership with Japan’s Chugai Pharmaceutical Co. valued at up to $1.085 billion, coupled with a $60.3 million private placement that strengthens its capital position through 2028. The Chugai Collaboration Under the agreement, Chugai will make…

Market News

Your Guide To Staying Informed In The Markets